6Clinical and Laboratory Standards Institute 2008. Performance standards for antimierobial susceptibility testing: eighteenth informational supplement M100-S18[S]. CLSI, 2008.
7Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis, 2006,43(Suppl 2):S43-S48.
8Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J ]. Lancet Infect Dis, 2008,8 (12) : 751-762.
9Gales AC,Jones RN,Sader HS. Global assessment of the antimicrobial activity of polymycin B against 54 731 clinical isolates of Gram-negtive bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J]. Clin Microbiol Infect, 2006,12(4):315- 321.
10Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections[J]. Drugs, 2007,67(13) : 1829-1849.
2DEVECI A,COBAN A Y,ACICBE O,et akin vitro effects of sulbactam combinations with different antibiotic groups against clinical Acineto-bacter baumannil isolates [J].J Chemother, 2012,24 (5) : 247-252.
3AYDEMIR H,AKDUMAN D,PISKIN N,et al.Colistin vs. the combination of colistin and rifamplcln for the treatment of earbapenem-resistant Aeinetobaeter baumannii ventilator-associated pneumonla[J]. Epidemiol Infect, 2013,141 ( 6 ) : 1214-1222.
4BOU R,GOMAR S,HERVAS F,et akEmdioation of a nosoeomial out- break of multidrug-resistant Aelnetobaeter baumannii infections after adjusting nursing workloads and reinforcing specific precautions [J]. Enferm Infect Microblol Clin, 2013,31 ( 9 ) : 584-589.
